Liver/Biliary Disorders News

Nearly twice as many hepatitis A virus-related deaths were reported in the United States from 2016 to 2022 compared with the previous 6 years, with individuals who use drugs or experience homelessness and unstable housing most at risk.

Acamprosate and oral naltrexone were associated with significantly improved alcohol consumption outcomes compared with placebo and could be used alongside psychosocial interventions as first-line treatment for alcohol use disorder.

BOSTON — LPCN 1148, an oral androgen receptor agonist, improved sarcopenia, hepatic encephalopathy and other biomarkers associated with end-stage liver disease among men with advanced cirrhosis and clinical decompensation.

BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.

BOSTON — After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented at The Liver Meeting.

BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.

BOSTON — Female adolescents and young adults have higher rates of liver-related mortality and a 50% higher risk for cirrhosis and decompensation after surviving their first presentation of alcoholic hepatitis, according to data.

Topline findings from an extension of the phase 2b ENLIVEN trial showed that pegozafermin sustained improvements in fibrosis and disease resolution for patients with nonalcoholic steatohepatitis at 48 weeks, 89bio announced.

BOSTON — Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE trial and presented at The Liver Meeting.

BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.